Grifols, S.A. (NASDAQ:GRFS) to Issue $0.09 Special Dividend

by · The Markets Daily

Grifols, S.A. (NASDAQ:GRFS – Get Free Report) declared a special dividend on Monday, June 22nd. Stockholders of record on Thursday, July 2nd will be given a dividend of 0.0945 per share by the biotechnology company on Thursday, July 9th. The ex-dividend date of this dividend is Thursday, July 2nd.

Grifols has a dividend payout ratio of 12.7% meaning its dividend is sufficiently covered by earnings. Analysts expect Grifols to earn $1.34 per share next year, which means the company should continue to be able to cover its $0.14 annual dividend with an expected future payout ratio of 10.4%.

Grifols Price Performance

Shares of NASDAQ:GRFS traded down $0.10 during midday trading on Tuesday, reaching $7.17. 429,640 shares of the company’s stock were exchanged, compared to its average volume of 652,838. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. The company’s 50 day simple moving average is $7.92 and its two-hundred day simple moving average is $8.51. Grifols has a 12 month low of $7.16 and a 12 month high of $11.14. The firm has a market capitalization of $4.88 billion, a PE ratio of 37.76, a price-to-earnings-growth ratio of 0.29 and a beta of 0.65.

Grifols (NASDAQ:GRFS – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The company had revenue of $2.32 billion for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. Equities research analysts expect that Grifols will post 1.06 earnings per share for the current fiscal year.

Institutional Trading of Grifols

A number of large investors have recently modified their holdings of GRFS. JPMorgan Chase & Co. raised its stake in shares of Grifols by 31.8% in the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock valued at $24,783,000 after acquiring an additional 600,118 shares in the last quarter. Integrated Quantitative Investments LLC acquired a new stake in Grifols in the third quarter valued at approximately $1,361,000. Envestnet Asset Management Inc. grew its holdings in Grifols by 80.2% during the 3rd quarter. Envestnet Asset Management Inc. now owns 515,853 shares of the biotechnology company’s stock worth $5,138,000 after acquiring an additional 229,661 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in shares of Grifols in the 3rd quarter valued at $1,156,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Grifols by 31.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 478,769 shares of the biotechnology company’s stock worth $4,476,000 after purchasing an additional 113,539 shares during the last quarter.

About Grifols

(Get Free Report)

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.

Further Reading